NYSE · Healthcare
CHEMED CORP (CHE)
As-reported financials and recent SEC filings for CHEMED CORP, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$2.53B
Net income
$265.2M
Net margin
10.5%
Diluted EPS
$18.34
ROE
27.1%
P/E (TTM)
25.3×
Market cap
$6.15B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.53B | $2.43B | $2.26B | $2.13B | $2.14B |
| Gross profit | $823.2M | $854.3M | $798.8M | $765.1M | $769.8M |
| Operating income | $338.2M | $366.5M | $340.6M | $343.5M | $343.0M |
| Net income | $265.2M | $302.0M | $272.5M | $249.6M | $268.6M |
| Diluted EPS | $18.34 | $19.89 | $17.93 | $16.53 | $16.85 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
11-K2026-06-24
View on EDGAR →42026-06-10
View on EDGAR →42026-05-29
View on EDGAR →42026-05-19
View on EDGAR →42026-05-19
View on EDGAR →42026-05-19
View on EDGAR →42026-05-19
View on EDGAR →42026-05-19
View on EDGAR →Go deeper on CHE
Search CHEMED CORP’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.